

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jinxin Fertility Group Limited

錦欣生殖醫療集團有限公司*

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock Code: 1951)

VOLUNTARY ANNOUNCEMENT

KEY OPERATING DATA FOR THE SIX MONTHS ENDED JUNE 30, 2026

This is a voluntary announcement made by Jinxin Fertility Group Limited (the “**Company**”) to keep the shareholders of the Company and potential investors informed of the latest business developments of the Company and its subsidiaries (the “**Group**”).

The board of directors (the “**Board**”) of the Company is pleased to announce that the number of new patient visits for infertility (“**NPVs**”) reached 24,169 for the six months ended June 30, 2026, representing an increase of 9.1% compared to the same period in 2025. The number of oocyte pick up cycles (“**OPU Cycles**”) for the six months ended June 30, 2026 was 14,653, representing a period-on-period increase of 6.1%.

For the six months ended June 30, 2026:

- **VIP Client Penetration:** The Group’s VIP client penetration rate continued to improve, with the Bisheng campus of Sichuan Jinxin Xinan Women and Children Hospital (Bisheng Campus) recording an increase of 0.9 percentage points and the newly opened campus of Shenzhen Zhongshan Obstetrics and Gynecology Hospital recording a 6.9 percentage point increase, both on a period-on-period basis.
- **Policy Alignment:** Actively responding to national initiatives in connection with promoting quality maternal and child health and the fostering of a fertility-friendly society, the number of third-generation IVF cycles in the Chengdu region recorded a period-on-period growth of 16.9%.
- **Service Expansion:** In response to changes in the market environment, the Company strategically adjusted its business focus, with IVF-related obstetrics services expanding by more than 80% period-on-period. This growth not only helped to address gaps in traditional obstetrics but also successfully reshaped the women’s health value chain, transitioning from “single delivery” to “maternity + reproductive services.”

For the six months ended June 30, 2026, the Group's business performance by region was as follows:

- **Greater Bay Area:** Following the commencement of operations of the new campus of the Group's Shenzhen Zhongshan Obstetrics and Gynecology Hospital, the number of NPVs increased by 30.1% as compared with the same period last year, driven by expanded hospital capacity and rising demand for services. The Group will continue to refine its full-service operations, implement diverse initiatives to boost customer conversion efficiency and steadily improve cyclical performance indicators.
- **Kunming and Wuhan region:** The Group's market reputation has continued to improve, with the number of OPU Cycles for the six months ended June 30, 2026 increased by 15.4% as compared to the same period in 2025.
- **Overseas:** Overseas operations demonstrated satisfactory growth, with the number of OPU Cycles reaching a record high and increasing 42.4% period-on-period.

The table below sets forth the number of NPVs for the six months ended June 30, 2026 and the three months ended March 31, 2026, with comparative figures for the corresponding periods in 2025:

Region	Number of NPVs ⁽¹⁾					
	For the six months		Period-on-period changes	For the three months		Period-on-period changes
	ended June 30, 2026	2025		ended March 31, 2026	2025	
Chengdu	10,601	10,541	0.6%	5,223	5,397	-3.2%
Greater Bay Area	4,837	3,719	30.1%	2,203	1,872	17.7%
Kunming and Wuhan	4,178	4,373	-4.5%	2,218	2,314	-4.1%
Overseas ⁽²⁾	4,553	3,518	29.4%	2,258	1,749	29.1%
Total	24,169	22,151	9.1%	11,902	11,332	5.0%

The table below sets forth the number of OPU Cycles for the six months ended June 30, 2026 and the three months ended March 31, 2026, with comparative figures for the corresponding periods in 2025:

Region	Number of OPU Cycles					
	For the six months		Period-on-period changes	For the three months		Period-on-period changes
	ended June 30, 2026	2025		ended March 31, 2026	2025	
Chengdu	6,724	7,111	-5.4%	2,814	3,035	-7.3%
Greater Bay Area	2,562	2,539	0.9%	1,121	1,088	3.0%
Kunming and Wuhan	2,377	2,059	15.4%	863	797	8.3%
Overseas ⁽²⁾	2,990	2,099	42.4%	1,318	1,002	31.5%
Total	14,653	13,808	6.1%	6,116	5,922	3.3%

Notes:

- (1) NPVs: Patients (including couples) who visit the Group's hospitals' department of reproductive medicine or assisted reproductive centers for the first time, have not previously established any medical records related to infertility or assisted reproduction at the Group's facilities, and have no prior reproductive medicine consultation records. This refers to the first registration for fertility assessment, infertility screening, or planned assisted reproductive treatment (intrauterine insemination or in-vitro fertilization).
- (2) The overseas business in 2025 included the Jinrui Medical Center in Laos and the Company has terminated its operations in Laos in 2025. Excluding the Group's business in Laos, the number of OPU cycles of Huntington Reproductive Center Medical Group in the US increased by 45.8% period-on-period.

The Group will continue to prioritize full-cycle reproductive health needs, in close alignment with the national three-tier prevention framework for birth defects, and will establish a comprehensive service loop encompassing reproductive genetics through to newborn screening. Building on its core business, the Group will expand into diversified healthcare segments, integrating multidisciplinary medical resources to support the transition from single-point diagnosis and treatment to full-cycle health management through refined, end-to-end care. This strategic approach is expected to foster the development of new and sustainable performance growth drivers.

The Company wishes to provide the shareholders and potential investors of the Company with a business update and the information contained herein is based on a preliminary assessment of the Group and the information currently available to the Company and is not based on any figure or information which has been audited or reviewed by the auditor of the Company. The above figures contained in this announcement are for illustrative purposes only, and do not constitute forward-looking statements or profit numbers.

Shareholders and potential investors of the Company are reminded to rationally deal with any information not officially released by the Company, and shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

By order of the Board
Jinxin Fertility Group Limited
Dong Yang
Chief Executive Officer,
Acting Chief Financial Officer
and Executive Director

Hong Kong, July 21, 2026

As at the date of this announcement, the Board comprises Mr. Dong Yang, Dr. Lyu Rong and Dr. Geng Lihong, as executive directors; Mr. Zhong Yong, as chairman and non-executive director, and Ms. Hu Zhe, Ms. Yan Xiaoqing and Mr. Chen Shuyun, as non-executive directors; and Dr. Chong Yat Keung, Dr. Li Jianwei, Mr. Wang Xiaobo and Mr. Ye Changqing, as independent non-executive directors.

** For identification purposes only*